# Gadeta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gadeta-b-v

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.gadeta.nl/
- Total disclosed funding: $7.6M
- Latest round: Series A (Mar 29, 2016)
- Investors on record: 3

## About

Gadeta B.V., based in the Netherlands, specializes in developing immunotherapy solutions for cancer treatment, harnessing gamma delta T cells to enhance therapeutic effectiveness and precision.Founded in 2015 and headquartered in Utrecht, Netherlands, Gadeta B.V. focuses on creating innovative cancer therapies. The company has engaged in two notable investment rounds, with the most recent round being a Series A in October 2023, raising EUR 7.000 mn from investors including Baxalta Ventures and Medicxi Ventures. On October 2, 2023, Gadeta was fully acquired by Clade Therapeutics, Inc., a portfolio company of Bristol-Myers Squibb Company. The financial terms of this transaction were not disclosed.Gadeta focuses on developing innovative immunotherapy solutions aimed at enhancing the treatment of various cancers. The company's core offerings center around its proprietary technology that harnesses the power of gamma delta T cells in the immune system, specifically targeting tumor cells. This approach is designed to improve patient outcomes by increasing the efficacy and precision of cancer treatments, thereby addressing significant unmet clinical needs. Gadeta's products are primarily utilized in clinical settings, with a clientele that includes hospitals, oncology centers, and research institutions across Europe and North America.The revenue model for Gadeta is structured around partnerships with healthcare institutions and potential licensing agreements. The company engages in B2B transactions, collaborating with hospitals and research organizations that incorporate its immunotherapy products into their treatment protocols. Revenue generation occurs through these partnerships, where clients may pay for access to Gadeta's therapies and related technologies. While specific pricing plans are not disclosed, flagship products associated with the company are likely to be integral to the revenue streams. This structured approach allows Gadeta to maintain a sustainable business model while continuing to innovate and develop its offerings in the competitive biopharmaceutical landscape.Following the recent acquisition by Clade Therapeutics, Gadeta's strategic future involves leveraging its preclinical cell therapy programs to enhance the development of stem cell-based medicines. This acquisition allows Clade to access Gadeta's innovative technology, thereby expanding its capabilities in the oncology sector. Future growth will also focus on integrating Gadeta’s therapies into broader clinical applications, with targeted plans for expansion into additional markets as part of Clade's strategic roadmap.

## Funding rounds

- Series A, Mar 29, 2016, $7.6M — Baxalta Ventures, Medicxi, Utrecht Holdings

## Investors

- Baxalta Ventures (https://capitalatlas.ai/funds/baxalta-ventures) — Series A
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A
- Utrecht Holdings (https://capitalatlas.ai/funds/utrecht-holdings) — Series A